AI agent disclosures in SEC filings
As of 2026-08-19, KALA BIO, Inc. (KALA) disclosed AI-agent language in 5 SEC filings since 2026-03-04 (source: Agentic 10-K, from SEC EDGAR).
Healthcare & clinical, IT & security ops
Researgency, Younet, Younet AI
5 filings since 2025-01-01. All EDGAR filings (opens in a new tab)
Stage and function are keyword-rule labels, not the company’s words.
Sentences copied from the filings, whitespace normalised.
“Following the discontinuation of the CHASE Phase 2b clinical trial of KPI-012 in September 2025 and the subsequent resolution of our obligations to Oxford Finance, our current operating focus is (i) the monetization or out-licensing of remaining biologics-related assets and (ii) development and commercialization planning for our licensed Researgency agentic AI platform (the “Researgency Platform”).”
“An agentic system can manage the entire workflow, while a conventional AI tool generally only answers individual questions.”
“ai, a platform designed to enable scalable, governed deployment of AI agents across research, documentation, and operational workflows.”
KALA BIO mentions ability to develop and commercialize Researgency agentic AI research platform.
“our ability to resume research and development activities for our MSC-S platform if we were to execute a strategic transaction or obtain significant additional funding, and our ability to develop and commercialize the Researgency agentic AI research platform;”
KALA BIO states plans for AI platform business and deployment of Researgency agentic AI platform.
“our plans and goals with respect to the AI platform business and the deployment of the Researgency agentic AI research platform, including the development of commercial arrangements with customers in the biotechnology and pharmaceutical industries;”
KALA BIO discusses market opportunity estimates for Researgency agentic AI research platform.
“This Quarterly Report on Form 10-Q may include statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by us and third parties as well as our estimates of potential market opportunities. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunity for the Researgency agentic AI research platform and KPI-012 include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.”
KALA BIO is transitioning to an AI platform-as-a-service model and planning development of its licensed Researgency agentic AI platform.
“We are in the process of evaluating and transitioning from historical biologics research and development (R&D) activities to an “AI platform-as-a-service” model intended to provide dedicated, on-premises artificial intelligence infrastructure solutions to biotechnology and pharmaceutical customers. Following the discontinuation of the CHASE Phase 2b clinical trial of KPI-012 in September 2025 and the subsequent resolution of our obligations to Oxford Finance, our current operating focus is (i) the monetization or out-licensing of remaining biologics-related assets and (ii) development and commercialization planning for our licensed Researgency agentic AI platform (the “Researgency Platform”). This transition is expected to impact our operating expenses, capital requirements, and sources and uses of cash as described further below.”
KALA BIO is transitioning to an AI platform-as-a-service model and planning development of its licensed Researgency agentic AI platform.
“We are in the process of transitioning from historical biologics research and development (R&D) activities to an “AI platform-as-a-service” model that provides dedicated, on-premises artificial intelligence infrastructure solutions to biotechnology and pharmaceutical customers. Following the discontinuation of the CHASE Phase 2b clinical trial of KPI-012 in September 2025 and the subsequent resolution of our obligations to Oxford Finance, our current operating focus is (i) the monetization or out-licensing of remaining biologics-related assets and (ii) development and commercialization planning for our licensed Researgency agentic AI platform (the “Researgency Platform”). This transition is expected to impact our operating expenses, capital requirements, and sources and uses of cash as described further below.”
KALA BIO aims to develop and commercialize the Researgency agentic AI research platform.
“our ability to resume research and development activities for our MSC-S platform if we were to execute a strategic transaction or obtain significant additional funding, and our ability to develop and commercialize the Researgency agentic AI research platform;”
KALA BIO describes plans for its Researgency agentic AI research platform and potential customer arrangements.
“our plans and goals with respect to the AI platform business and the deployment of the Researgency agentic AI research platform, including the development of commercial arrangements with customers in the biotechnology and pharmaceutical industries;”
KALA BIO discusses market data and assumptions for its Researgency agentic AI research platform opportunity.
“This Quarterly Report on Form 10-Q may include statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by us and third parties as well as our estimates of potential market opportunities. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunity for the Researgency agentic AI research platform and KPI-012 include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.”
KALA BIO is transitioning to an AI platform-as-a-service model and planning commercialization of its licensed Researgency Platform.
“We are in the process of evaluating and transitioning from historical biologics research and development (R&D) activities to an “AI platform-as-a-service” model intended to provide dedicated, on-premises artificial intelligence infrastructure solutions to biotechnology and pharmaceutical customers. Following the discontinuation of the CHASE Phase 2b clinical trial of KPI-012 in September 2025 and the subsequent resolution of our obligations to Oxford Finance, our current operating focus is (i) the monetization or out-licensing of remaining biologics-related assets and (ii) development and commercialization planning for our licensed Researgency agentic AI platform (the “Researgency Platform”). This transition is expected to impact our operating expenses, capital requirements, and sources and uses of cash as described further below.”
Kala licensed Researgency AI platform and plans to enable AI agents for biotech.
“Through its exclusive worldwide license for the Researgency AI research platform from Younet, Kala intends to serve as the dedicated AI infrastructure partner for the biotechnology industry, enabling organizations of all sizes to unlock the value of their proprietary biological data without surrendering control. Kala is advancing an agentic transformation strategy for biomedical organizations through Researgency.ai, a platform designed to enable scalable, governed deployment of AI agents across research, documentation, and operational workflows. The Company’s focus on enterprise security, real-time performance, and seamless integration positions it at the forefront of innovation in the life sciences AI sector.”
Kala believes the future of biomedical innovation is in agentic systems.
“Kala believes the future of biomedical innovation is in agentic systems. For more information, visit www.kalarx.com and www.Researgency.ai”
KALA plans to develop and commercialize the Researgency agentic AI research platform.
“our ability to resume research and development activities for our MSC-S platform if we were to execute a strategic transaction or obtain significant additional funding, and our ability to develop and commercialize the Researgency agentic AI research platform;”
KALA plans deployment of the Researgency agentic AI research platform to customers.
“our plans and goals with respect to the AI platform business and the deployment of the Researgency agentic AI research platform, including the development of commercial arrangements with customers in the biotechnology and pharmaceutical industries;”
KALA estimates market opportunity for the Researgency agentic AI research platform.
“This Annual Report on Form 10-K includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by us and third parties as well as our estimates of potential market opportunities. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunity for the Researgency agentic AI research platform and KPI-012 include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.”
KALA BIO licensed Researgency AI platform from Younet to test feasibility of an agentic AI research platform for biotech.
“On March 3, 2026 (subsequent to the fiscal year ended December 31, 2025), we entered into an exclusive license for the Researgency AI research platform (“Researgency”) from Younet AI (“Younet”), through which we intend to test and assess the feasibility of offering a dedicated AI infrastructure partner for the biotechnology industry. Our goal is to enable companies of all sizes to unlock the value of their proprietary biological data without surrendering control of it through the development of a specialized agentic AI research platform.”
Defines agentic AI as autonomous goal-directed systems that break down tasks, self-correct, and coordinate.
“One variation of “Agentic” AI is that it describes a system's ability to act on data. A typical AI assistant responds to questions when asked. An agentic AI system is generally designed to autonomously pursue specific goals, breaking down complex objectives into smaller tasks, completing each one step by one, assessing results, and adjusting its strategy based on what it learns along the way. Typical capabilities of agentic AI systems may include goal-directed execution, external tool and database integration, context persistence across extended workflows, self-correction when intermediate outputs fail to meet quality criteria, and multi-agent coordination in which specialized agents perform discrete tasks orchestrated into a unified deliverable.”
Explains practical value of agentic AI for complex multi-step biotechnology research workflows versus conventional AI.
“In biotechnology research, this difference becomes practically important. Analyzing a failed clinical trial dataset for subgroup signals is a complex, multi-step process, involving loading and cleaning data, developing and testing hypotheses, cross-referencing findings with published literature, evaluating statistical significance, ranking results by biological plausibility, and preparing a structured report for scientific review. An agentic system can manage the entire workflow, while a conventional AI tool generally only answers individual questions.”
KALA plans to implement an Agentic Company strategy in biomedicine using Younet AI technology.
“The Company believes this on-premises, data-sovereign approach represents a fundamentally different model from the centralized AI platforms currently operating in the life sciences space. While established AI drug discovery companies, including well-funded, publicly traded platforms with billion-dollar market capitalizations, typically require clients to upload proprietary data to centralized cloud environments, KALA’s architecture is designed from inception to go to the client, not the other way around. The Company believes this distinction is critical in an industry where intellectual property, trade secrets, and regulatory-sensitive data represent the most valuable assets a company possesses. Younet’s current go to market strategy is focused on morphing and tech augmenting existing operating companies into Agentic Companies where a large bulk of repeat and time consuming tasks and research are passed on to teams of proprietary agents. KALA intends to build on top of this approach and implement Agentic Company strategy in biomedical field.”
KALA licenses Researgency, a biomedical AI platform from Younet AI which has deployed over 100 custom agents.
“Researgency is a proprietary biomedical AI research platform licensed to KALA by Younet AI, a specialized artificial intelligence development firm with experience deploying over 100 custom AI agents for enterprise clients across healthcare, technology, and life sciences sectors.”
KALA deploys custom AI agents configured for each client's therapeutic focus and data types.
“Custom Agent Architecture: Purpose-built AI agents are configured specifically for each client’s therapeutic focus areas, data types, and research objectives, not generic, one-size-fits-all models.”
KALA features purpose-built AI agents tailored to client datasets and therapeutic areas.
“Deep Customization: Each deployment features purpose-built AI agents tailored to the client’s specific datasets and therapeutic areas, creating high switching costs and long-term client retention.”
KALA expects operational expertise in biomedical AI agents to grow with each new deployment.
“Platform Network Effects: As KALA deploys across multiple clients, the Company’s understanding of biomedical AI agent design, RAG pipeline optimization, and deployment best practices should increase — creating an operational expertise moat that is expected to grow with each new deployment.”
KALA licensed Researgency from Younet AI for biotechnology and plans potential expanded AI agent deployment.
“Under the Agreement, KALA has secured exclusive worldwide license rights to the Researgency platform within the biotechnology field (as defined in the Agreement) and has received initial platform access to evaluate and demonstrate its capabilities. The exclusivity applies to the custom, dedicated platform configured for KALA and does not restrict Younet from operating its standard, generally available, multi-tenant SaaS platform. The Company intends to assess the platform’s performance during the 12-month initial term and, subject to satisfactory results, may elect to extend the Agreement for successive 12-month renewal terms, which would include expanded deployment of custom biotechnology-focused AI agents, RAG pipeline optimization, and full-scale integration with the Company’s proprietary data systems.”
Younet has developed and deployed over 100 custom AI agents for enterprise clients.
“Younet is a specialized artificial intelligence development firm with expertise in deploying custom large language models (“ LLMs ”), retrieval-augmented generation (“ RAG ”) pipelines, and scalable AI platforms, and has developed and deployed over 100 custom AI agents for enterprise clients;”
Platform includes all custom AI agents developed by Younet for KALA.
““ Platform ” means the Researgency biomedical AI research platform, including all custom AI agents, LLM configurations, RAG pipelines, user interfaces, APIs, dashboards, and supporting infrastructure developed by Younet for KALA under this Agreement.”
Platform will support deployment of purpose-built AI agents for clients.
“Custom Agent Configuration . The Platform shall support the deployment of purpose-built AI agents configured specifically for each client’s therapeutic focus areas, data types, and research objectives, rather than generic, multi-purpose models.”
Younet assigns all custom AI agents and work product to KALA.
“Platform IP — Work Product. All Deliverables, custom AI agents, biomedical-specific configurations, training data models, and other work product under Researgency platform developed by Younet specifically for KALA under this Agreement (collectively, “ Work Product ”) shall be the sole and exclusive property of KALA. Younet hereby assigns, and agrees to assign, to KALA all right, title, and interest in and to the Work Product, including all Intellectual Property rights therein. Younet shall execute all documents and take all actions reasonably necessary to perfect KALA’s ownership of the Work Product. KALA shall execute all documents and take all actions reasonably necessary to perfect/secure/transfer KALA’s ownership of the Work Product at Younet direction.”
Parties may agree to develop additional custom AI agents via change order.
“Additional Agent Development. The Parties may mutually agree to the development of additional custom AI agents or platform enhancements beyond the Initial and Renewal Deliverables, subject to the execution of a written change order or amendment specifying the scope, timeline, and additional compensation for such work.”